“Pharmacoepidemiology, impacts of anxiety disorders and anxiolytic abuse before and during the COVID-19 pandemic”, RSD, vol. 11, no. 5, p. e36111528340, Apr. 2022, doi: 10.33448/rsd-v11i5.28340.